Salmonella

METHOD AND REAGENTS FOR ULTRASENSITIVE IMMUNOASSAY

Resumen de: US20260079158A1

Disclosed are assays, reagents, and methods for ultrasensitive detection of target molecules. The assay comprises fusion proteins including binding moieties, such as antibodies, nanobodies (VHH/VNAR), or aptamers, linked to nonfunctional fragments of a protein. In the presence of a target molecule, the binding moieties recognize distinct target regions and bring the protein fragments into close proximity, reconstituting a functional protein that generates a detectable signal. Linkers connecting the fusion components may be flexible peptides or polypeptides that spontaneously form dimers, trimers, or tetramers, thereby providing multivalent fusion proteins with enhanced sensitivity. The reconstituted protein may produce luminescent, fluorescent, colorimetric, or spectroscopic signals detectable by microplate readers, handheld luminometers, or lateral flow devices. The invention encompasses solid-phase, homogeneous, and lateral flow assay formats for detecting viruses, bacteria, proteins, peptides, or small molecules, including GLRaV-3, SARS-CoV-2, PSA, and E. coli. The disclosed assays exhibit improved specificity, reduced background, and enhanced signal-to-noise ratios.

COMPOSITIONS AND METHODS FOR TREHALOSE PHOSPHOLIPIDS

Resumen de: US20260078140A1

Provided herein are compositions of trehalose phospholipids and uses thereof, e.g., compounds and compositions comprising 6,6′-diphosphatidyltrehalose (diPT) and analogs thereof with modifications of the diPT chemical scaffold, that bind and agonize Mincle, and the use thereof as adjuvants.

THERAPEUTIC AGENTS AND COMPOSITIONS AND RELATED METHODS

Resumen de: AU2024219856A1

- 41 The invention relates to methods of treating or preventing a disease or condition caused by or associated with a gram-negative bacterial infection in a subject in need thereof and compositions for use in such methods. More particularly, the present invention relates to agents and compositions, including concanavalin A, lactoferrin, colostrum and Ig from colostrum for use in the treatment or prevention of a disease or condition caused by or associated with a gram-negative bacterial infection and methods of using such agents and compositions.

脱酸素化リポ多糖（ＬＰＳ）、天然非毒性ＬＰＳおよびそれらの使用

Resumen de: EP4512482A2

The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being:- devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and- substituted at position C6' of the non-reducing end of their lipid A domain by a hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group.It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject.

噬菌体、沙门氏菌属细菌溶菌剂、组合物及沙门氏菌属细菌的防治方法

Resumen de: EP4692335A1

An aim of the present disclosure is: (i) to provide a novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, or a bacteriolytic agent consisting of the same; (ii) to provide a bacteriophage having a wide host range for bacteria of the genus Salmonella, or a bacteriolytic agent consisting of the same; (iii) to provide a host-specific bacteriophage or an effective Salmonella bacteriolytic agent consisting of the same; or (iv) provide a bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, or a bacteriolytic agent consisting of the same. The present disclosure provides: a bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same.

PNEUMONIA VACCINE

Resumen de: WO2026054672A1

The invention relates to the field of health care, and more particularly to the prevention of infections that cause pneumonia and other illnesses using an immunogenic protein containing fragments of the proteins FliC, PspA, OmpA and PE, connected by rigid linkers, wherein: - the FliC protein fragment contains SEQ ID NOs: 2 and 3 connected to one another by a flexible linker; - the PspA protein fragment contains SEQ ID NO: 4; the OmpA protein fragment contains SEQ ID NOs: 5-8 connected to one another by flexible linkers; - the PE fragment contains SEQ ID NO: 9. Also proposed are a host cell and a method for producing the protein. The immunogenic protein is suitable for use as a broad-spectrum polyvalent vaccine and exhibits a marked protective effect against Streptococcus pneumoniae, Haemophilus influenzae and Klebsiella pneumoniae, as well as providing for production efficiency and safety.

PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: EP4706672A1

A pharmaceutical composition, and a preparation method therefor and a use thereof. The pharmaceutical composition comprises a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or adjuvant. The first active ingredient is a microbial agent comprising any one or more of staphylococcus aureus, bordetella pertussis, diphtheria toxoid, tetanus toxoid, typhoid bacillus or salmonella paratyphi. The second active ingredient comprises polyinosinic acid, polycytidylic acid, and a vitamin. The pharmaceutical composition relates to an artificial active immunization therapy for tumors, and can "stimulate" the entire immune system, so that the therapy of using bacteria to stimulate a human immune system so as to kill cancer cells is quite stable and reliable, and the lives of cancer patients can be significantly saved and prolonged. Additionally, the pharmaceutical composition has extremely high safety, extremely small toxic and side effects, and low preparation costs.

SYSTEM AND METHOD FOR DETECTING, ENUMERATING, OR EXTRACTING MICROORGANISMS IN A SAMPLE

Resumen de: WO2024227138A1

A system and method for detecting, enumerating, or extracting microorganisms in a sample is disclosed. Target microorganisms, such as Salmonella bacteria, may be of interest. Magnetic beads may be bound to the target microorganisms. After which, the bead-bound cells may be isolated. For example, a magnetic field may be applied in order to separate the target cells (with the magnetic beads attached thereto) and move then to a predetermined section of the well. Agar, or other immobilizing agent, may be added to the wells in order to immobilize the target cells. After which, the target cells are incubated and periodically analyzed to determine whether the target cells are growing, thereby indicating that the microorganisms are contained within the well.

SYSTEMS, METHODS, AND COMPOSITIONS FOR THE DETECTION OF MICROBES

Resumen de: AU2024264505A1

Provided are non-naturally occurring systems, methods, and compositions for the detection of microbes. The disclosure relates to the detection of an antigen specific to a microbe, such as a foodborne, an environment-borne, and a bloodborne bacteria, using capture antibody and moiety, detector antibody and moiety, and a light-emitting particle.

一种重组甲型副伤寒沙门菌及其用途

Resumen de: CN121628795A

本发明提供了一株重组表达Vi多糖的甲型副伤寒沙门菌株，以基因工程技术将来自伤寒沙门菌的表达Vi多糖的viaB操纵子克隆到甲型副伤寒沙门菌基因组中，实现Vi多糖在甲型副伤寒沙门菌中的表达；进一步，以一个组成性强启动子(Tac启动子)取代viaB天然启动子实现 Vi 多糖在体外培养条件下的高表达；进一步，将该菌株的msbB基因敲除以降低LPS的酰基化水平，减低LPS毒性；以该菌株制备的囊泡疫苗可诱导针对两种血清型的免疫保护作用。

アジュバントを全く含まないカチオン性多糖ナノ粒子を介して不活性化全細菌を送達するための系を含むワクチン組成物

Resumen de: CN120712079A

The present invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition comprising killed intact bacteria intended for use in mammals and birds, said bacteria being wrapped with a cationic agent, in particular cationic nanoparticles.

Lateral flow strip based on loop-mediated isothermal amplification for detection of Salmonella

Resumen de: KR20260030992A

본 발명은 살모넬라 검출을 위한 고리매개등온증폭법 기반 측방유동스트립에 관한 것으로, 보다 상세하게는 고리매개등온증폭(loop-mediated isothermal amplification)용 프라이머 세트; 상기 프라이머 세트에 의해 증폭되는 증폭산물에 특이적으로 결합하는 프로브; 및 측방유동스트립(lateral flow strip);을 포함하는, 살모넬라 속 균을 검출하기 위한 측방유동검사(lateral flow assay) 키트 및 상기 키트를 이용한 살모넬라 속 균의 검출방법에 관한 것이다.

BIFIDOBACTERIUM LONGUM SUBSP. LONGUM, AND USE THEREOF IN INHIBITING BACTERIA, RELIEVING COLITIS, AND MITIGATING INFLAMMATORY BONE LOSS

Resumen de: WO2026045196A1

A Bifidobacterium longum subsp. longum dipro-017. The Bifidobacterium longum subsp. longum dipro-017 used has the ability to metabolize tryptophan to produce indole-3-lactic acid, can inhibit the pathogenic bacteria Salmonella Typhimurium, Staphylococcus aureus, and Escherichia coli, and can effectively mitigate weight loss caused by ulcerative colitis, improve a DAI score, improve colon length, mitigate the content of lipopolysaccharide (LPS) in blood, and increase the level of anti-inflammatory cytokine IL-10, as well as mitigate the content of bone metabolism indicators tartrate-resistant acid phosphatase (TRAP) and N-terminal propeptide of type I procollagen (PINP) in blood.

METHOD OF MAKING CHEMILUMINESCENT 1,2-DIOXETANES

Resumen de: WO2026047187A1

The invention relates to a method of making a 1,2-dioxetane, the method comprising reacting a naphthalene endo peroxide (NEPO) with the double bond of an enol ether to form the 1,2-dioxetane. The 1,2-dioxetanes are of great commercial interest for a variety of applications, such as singlet oxygen detection, enzyme detection and pathogen (e.g., Salmonella spp. and Listeria spp.) detection.

ORAL VACCINE AGAINST MULTIPLE DIARRHEA-CAUSING PATHOGENS

Resumen de: WO2026041729A1

A vaccine comprising effective amounts of i) E. coli colonization factor antigens comprising CFA/I, CS3, CS5 and CS6 antigens; ii) a heat labile enterotoxin B subunit antigen being an LCTBA protein; and iii) an adjuvant being double mutant (R192G/ L211A) of E. coli heat-labile toxin (dmLT), for use in inducing protective immunity against diarrheal disease caused by Salmonella spp. and/or Shigella spp.

ANTI-ETEC ADHESIN PROTEIN ANTIBODIES AND METHODS OF USE

Resumen de: WO2026044176A1

The invention provides anti-enterotoxigenic E. coli (ETEC) adhesin protein antibodies and methods of using the same. One embodiment is an isolated antibody that binds ETEC coli surface antigen 3 (CS3) protein and ETEC coli surface antigen 6 (CS6) protein, wherein the antibody comprises a CS3/CS6 VHH binding domain comprising the following complementary-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of GFTFEDYA (SEQ ID NO: 19); (b) a CDR-H2 comprising the amino acid sequence of INMSDGST (SEQ ID NO: 20); and (c) a CDR-H3 comprising the amino acid sequence of AANLTGPSGGGLPGYNYDY (SEQ ID NO: 21). Also disclosed are antibodies comprising said CS3/CS6 binding VHH and a binding domain capable of binding to an ETEC adhesin protein selected from colonization factor antigen I adhesin subunit E (CfaE), coli surface antigen 1 (CS1), coli surface antigen 4 (CS4), coli surface antigen 14 (CS14), coli surface antigen 17 (CS17), coli surface antigen 19 (CS19), and coli surface antigen 2 (CS2).

INACTIVATED SALMONELLA VACCINE FORMULATIONS

Resumen de: WO2026043873A1

The present disclosure provides formulations, kits, and vaccines directed to immunization of animals against Salmonella. Methods of usng the formulations, kits, and vaccines for protection of avians against one or more species of Salmonella are also provided. For instance, the formulations, kits, and vaccines can induce an immune response in an animal against a Salmonella infection in which the Salmonella infection is caused by more than one Salmonella group bacterium (e.g., a Group B bacterium, a Group C bacterium, and a Group D bacterium).

ORAL VACCINE AGAINST MULTIPLE DIARRHEA-CAUSING PATHOGENS

Resumen de: EP4699617A1

A vaccine comprising effective amounts of i) E. coli colonization factor antigens comprising CFA/I, CS3, CS5 and CS6 antigens; ii) a heat labile enterotoxin B subunit antigen being an LCTBA protein; and iii) an adjuvant being double mutant (R192G/ L211A) of E. coli heat-labile toxin (dmLT), for use in inducing protective immunity against diarrheal disease caused by Salmonella spp. and/or Shigella spp.

GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS

Resumen de: WO2024218333A1

The present invention relates to compounds of formula (la) that block invasion-associated pathogenicity of Salmonella Typhimurium by inhibiting the activity of the transcription factor HilD. These compounds are useful in the treatment or prophylaxis of Salmonella infections (salmonellosis).

免疫原性组合物

Resumen de: WO2025021712A1

The present invention relates to immunogenic compositions comprising antigens from Salmonella enterica serovar Typhimurium (S. Typhimurium), Salmonella enterica serovar Enteritidis (S. Enteritidis), and Salmonella enterica serovar Typhi (S. Typhi). The present invention further relates to methods and uses of compositions comprising GMMA for boosting an immune response to an S. Typhi antigen, vaccines comprising the immunogenic compositions and methods and uses of the immunogenic compositions.

免疫原性组合物

Resumen de: WO2025021695A1

The present invention relates to immunogenic compositions comprising outer membrane vesicles (OMVs) adsorbed to an aluminium hydroxide adjuvant, whereby the aluminium hydroxide adjuvant is quenched. The present invention also relates to the use of the immunogenic compositions for providing protection against diseases caused by Gram-negative bacteria. The present invention also relates to a method for reducing particle aggregation and/or average particle diameter in compositions comprising OMVs and an aluminium hydroxide adjuvant.

HOST-DIRECTED THERAPIES FOR SALMONELLA AND FRANCISELLA INFECTION

Resumen de: WO2026039487A1

The invention relates to small molecule compounds that are useful as antimicrobial agents, pharmaceutical compositions comprising the compounds, and the use of the compounds in the treatment of subjects with microbial infections.

Pharmaceutical Composition, Preparation Method and Use Thereof

Resumen de: US20260048111A1

The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.

GENETICALLY MODIFIED BACTERIA FOR GENERATING VACCINES

Resumen de: US20260048107A1

A vaccine is disclosed which comprises a pharmaceutically acceptable carrier and Gramnegative bacteria, genetically modified to express: at least one disease-associated antigen, linked to a signal sequence belonging to a type II secretion system; and the at least one disease-associated antigen linked to a signal sequence belonging to a type III secretion system. Uses thereof are also disclosed.

Methods for Vaccinating against Salmonella Species

Nº publicación: US20260048109A1 19/02/2026

Solicitante:

UNIV OF MARYLAND BALTIMORE [US]
University of Maryland, Baltimore

Resumen de: US20260048109A1

Provided herein are methods for vaccinating a subject against a Salmonella species, including typhoidal and non-typhoidal Salmonella species and serovars thereof with an Escherichia coli J5 dLOS/OMP vaccine. The vaccine is cross-reactive with the lipopolysaccharide conserved inner core region of the Salmonella species and cross-protective with the non-typhoidal Salmonella species. Vaccination reduces the likelihood of or prevents the onset of a salmonella infection. Also provided is a method of immunizing against antimicrobial resistant Salmonella species by complementing the J5 dLOS/OMP vaccine with a Salmonella species-specific vaccine.